Arguments in favour of remdesivir for treating SARS-CoV-2 infections

Int J Antimicrob Agents. 2020 Apr;55(4):105933. doi: 10.1016/j.ijantimicag.2020.105933. Epub 2020 Mar 6.
No abstract available

Keywords: Betacoronavirus; COVID-19; Coronavirus disease 2019; Remdesivir; SARS-CoV-2; Wuhan pneumonia.

Publication types

  • Editorial

MeSH terms

  • Adenosine Monophosphate / analogs & derivatives*
  • Adenosine Monophosphate / therapeutic use
  • Alanine / analogs & derivatives*
  • Alanine / therapeutic use
  • Animals
  • Antiviral Agents / therapeutic use*
  • Betacoronavirus / drug effects*
  • Betacoronavirus / enzymology
  • COVID-19
  • Clinical Trials as Topic
  • Coronavirus Infections / drug therapy*
  • DNA-Directed RNA Polymerases / antagonists & inhibitors
  • Humans
  • Pandemics
  • Pneumonia, Viral / drug therapy*
  • SARS-CoV-2

Substances

  • Antiviral Agents
  • remdesivir
  • Adenosine Monophosphate
  • DNA-Directed RNA Polymerases
  • Alanine

Supplementary concepts

  • COVID-19 drug treatment